Emerging evidence underscores the role of RIG-I (Ddx58) as a critical regulator of CD8+ tumor-infiltrating lymphocyte (TIL) function, implicating RIG-I as an immune checkpoint (67, 68). Here, RIGI is linked to neoplasm.